XML 79 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2021
$ / shares
shares
Jul. 08, 2020
May 03, 2019
Feb. 08, 2019
$ / shares
shares
Oct. 01, 2016
May 06, 2016
Feb. 08, 2016
shares
Nov. 30, 2021
USD ($)
$ / shares
shares
Aug. 31, 2021
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
Nov. 21, 2020
USD ($)
shares
Nov. 19, 2020
$ / shares
shares
Sep. 30, 2019
USD ($)
shares
Aug. 31, 2019
USD ($)
$ / shares
Feb. 28, 2017
Aug. 26, 2016
Feb. 17, 2016
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Jan. 31, 2022
shares
Aug. 05, 2021
Jun. 29, 2021
$ / shares
shares
May 17, 2021
$ / shares
Mar. 12, 2020
$ / shares
shares
Dec. 31, 2019
shares
May 09, 2018
$ / shares
Sep. 25, 2017
USD ($)
Mar. 21, 2016
$ / shares
shares
Equity (Details) [Line Items]                                                            
Percentage of common shares issued and outstanding                                       1.50%                    
Common stock, par value (in Dollars per share) | $ / shares                                   $ 0.001   $ 0.001 $ 0.001                 $ 0.001
Ordinary shares authorized                                                           360,000,000
Agreement, description           the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.                 the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.                            
Issuance of common shares, shares                   1,111,112                                        
Financial amendment, description     the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock.                                                      
Consulting service, description                                   Pursuant to the agreements, the Company issued 644,972 shares of the Company’s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable.                        
Common stock, shares issued                                   30,307,329   28,926,322 24,420,526     50,000     644,972      
Consulting fees (in Dollars) | $                                   $ 4,514,800   $ 4,514,800                    
Stock subscription receivable (in Dollars) | $                                   $ 2,031,660   2,257,400 $ 3,160,360                  
Due to related parties consideration (in Dollars) | $                           $ 4,872,340           $ 2,693,548 $ 1,717,051                  
Common stock price per share (in Dollars per share) | $ / shares                           $ 7                     $ 2.25          
Common stock, authorized                                   100,000,000   100,000,000 100,000,000                  
Shares per price (in Dollars per share) | $ / shares                                               $ 5            
Shares issued                                           1,306,007                
Warrant issued                       200,000                                    
Exercise price (in Dollars per share) | $ / shares                       $ 2.25                                    
Warrant term                       5 years                                    
Issuance of common stock                                         3,384,615                  
Aggregate common stock shares               673,605                   915,856   915,856                    
Convertible promissory note value (in Dollars) | $                   $ 2,500,000                                        
Description of public offering                                             the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.              
Issuance of common stock for debt (in Dollars) | $                                   $ 40,448 $ 11,119,452 $ 7,615,331                  
Gross proceeds from exercise of warrants (in Dollars) | $               $ 4,244,452                                            
Consulting agreement desciption In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021.                                  In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021. In January 2022, the Company agreed to pay the deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.                         
Common shares, issued                                   75,000                        
Consulting and advisory services amount (in Dollars) | $                                   $ 169,500                        
Consulting and advisory services value per share (in Dollars per share) | $ / shares                                   $ 2.26                        
Number of investors (in Dollars per share) | $ / shares                                                       $ 2    
2016 Equity Incentive Plan [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split                                 157,050                          
Common stock issued pre-stock split                                 50,000                          
Private Placement [Member]                                                            
Equity (Details) [Line Items]                                                            
Aggregated capital contributions (in Dollars) | $                                         $ 7,615,331                  
Number of investors                                         45                  
Purchase price per share (in Dollars per share) | $ / shares                                         $ 2.25                  
Number of investors (in Dollars per share) | $ / shares                                         $ 2.25                  
IPO [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued to professional investors                 2,354,145                                          
Issuance of common stock for debt (in Dollars) | $                 $ 6,875,000                                          
Legal fees (in Dollars) | $                 $ 850,429                                          
Series A Warrants [Member]                                                            
Equity (Details) [Line Items]                                                            
Warrants exercised 673,405             673,405                                            
Warrants exercise price (in Dollars per share) | $ / shares $ 6.3             $ 6.3                                            
Series B Warrants [Member]                                                            
Equity (Details) [Line Items]                                                            
Warrants exercised 200             200                                            
Warrants exercise price (in Dollars per share) | $ / shares $ 10             $ 10                                            
Kameyama [Member]                                                            
Equity (Details) [Line Items]                                                            
Issuance of common shares, shares                     24,694                                      
Unpaid consulting fees (in Dollars) | $                     $ 49,388                                      
Articles of Incorporation [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock, par value (in Dollars per share) | $ / shares                                                   $ 0.001        
Articles of Incorporation [Member] | Minimum [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock, authorized                                                   20,000,000        
Articles of Incorporation [Member] | Maximum [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock, authorized                                                   100,000,000        
View Trade Securities Inc. [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock, shares issued                                         60,000                  
Consulting fees (in Dollars) | $                                         $ 135,000                  
Placement agent agreement, description   Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.                                                        
Restricted common shares                                               6,000            
WallachBeth Capital LLC [Member]                                                            
Equity (Details) [Line Items]                                                            
Shares issued                                               6,000            
Consulting Agreement [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock price per share (in Dollars per share) | $ / shares                                         $ 2.9                  
Unrestricted common shares 316,934             316,934                         50,000                  
Service fee amount (in Dollars) | $               $ 1,478,590                                            
Consulting Agreement [Member] | Minimum [Member]                                                            
Equity (Details) [Line Items]                                                            
Price per share (in Dollars per share) | $ / shares $ 2.31             $ 2.31                                            
Consulting Agreement [Member] | Maximum [Member]                                                            
Equity (Details) [Line Items]                                                            
Price per share (in Dollars per share) | $ / shares $ 6.3             $ 6.3                                            
Non Related Parties [Member]                                                            
Equity (Details) [Line Items]                                                            
Debt conversion, description                                   a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock.   b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock.     c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock.     d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock.     e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock.   f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock.   a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock.   b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock.     c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company’s common stock, and warrants to purchase 162,908 shares of the Company’s common stock.     d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company’s common stock, and warrants to purchase 126,530 shares of the Company’s common stock.     e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock.   f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,121 shares of the Company’s common stock.                    
BioLite [Member]                                                            
Equity (Details) [Line Items]                                                            
Issuance of common shares, shares       74,997,546                                                    
BioKey [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split       1,642,291                                                    
Issuance of common shares, shares       29,561,231                                                    
Number of investors (in Dollars per share) | $ / shares       $ 1.5                                                    
Share Exchange Agreement [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split             164,387,376                                              
Common stock issued pre-stock split             52,336,000                                              
Share Exchange Agreement One [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split             166,273,921                                              
Common stock issued pre-stock split             52,936,583                                              
Share Exchange Agreement Two [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split             163,159,952                                              
Common stock issued pre-stock split             51,945,225                                              
Percentage of common shares issued and outstanding             79.70%                                              
Percentage of issued share capital             100.00%                                              
Share Exchange Agreement Three [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split             166,273,921                                              
Common stock issued pre-stock split             52,936,583                                              
Share Exchange Agreement Four [Member]                                                            
Equity (Details) [Line Items]                                                            
Common stock issued post-stock split             205,519,223                                              
Common stock issued pre-stock split             65,431,144                                              
Collaborative Arrangement [Member]                                                            
Equity (Details) [Line Items]                                                            
Issuance of common shares, shares                         428,571                                  
Consulting agreement, description         On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000.                                                  
Issuance of common shares (in Dollars) | $                         $ 3,000,000                                  
Co-Dev Agreement [Member]                                                            
Equity (Details) [Line Items]                                                            
Due to related parties (in Dollars) | $                                                         $ 3,000,000  
Consulting Agreement [Member]                                                            
Equity (Details) [Line Items]                                                            
Shares issued                                         521,887                  
Consulting Agreement [Member] | Minimum [Member]                                                            
Equity (Details) [Line Items]                                                            
Price per share (in Dollars per share) | $ / shares                                         $ 2                  
Consulting Agreement [Member] | Maximum [Member]                                                            
Equity (Details) [Line Items]                                                            
Price per share                                         3.68